NuCana : Presentation - May 2026 (286614)

Published: 2026-05-06 05:18:08 ET NCNA

Published on 05/06/2026 at 05:18 am EDT

A New Era in Oncology

nucana.com

Corporate Presentation

May 2026

Harnessing the Power of Phosphoramidate Chemistry

Transforming Nucleoside Analogs into ProTides

16 FDA Approved

Anti-Cancer Nucleoside Analogs

22 FDA Approved

Anti-Viral Nucleoside Analogs

Including: Including:

Limitations of Nucleoside Analogs

B & Toxicts

Breakdown

Off-target toxicity

yproduc

Dependent on

Uptake

transporters

to enter

cells

Activation

generation of

Inefficient

metabolites

active

Administration

Poor PK leads to

Challenges

sub-optimal

dosing

Hepatitis C

COVID-19

tenofovir alafenamide

HIV & Hepatitis B

Transformed novel nucleoside analog

Highly effective treatment for chronic Hepatitis C infection

Sales: $74 billion1

Transformed nucleoside analog: Viread® (tenofovir disoproxil fumarate)

More effective & safer treatment for HIV & HBV than Viread®

Sales: $135 billion2

Transformed novel nucleoside analog

Treatment for COVID-19

Sales: $17 billion3

1 Sovaldi + Harvoni + Epclusa + Vosevi cumulative sales through December 31, 2025

2 Genvoya + Descovy + Odefsey + Biktarvy + Symtuza + Vemlidy cumulative sales through December 31, 2025

3 Veklury cumulative sales through December 31, 2025

Transformed novel nucleoside analog: 3'-dA

Profoundly impacts gene expression in cancer cells

Targets the tumor microenvironment

Transformed nucleoside analog: FUDR

Targeted Thymidylate Synthase Inhibitor

Induces DNA damage

INDICATION

COMBINATION

PRE-CLINICAL

PHASE 1

PHASE 2

NuTide:701

Study

NuTide:701

Study

NuTide:303

Study

Solid Tumors

Melanoma

Solid Tumors

monotherapy

pembrolizumab

NCNA

Cash & Cash Equivalents

December 31, 2025

~$32.6 million#

Cash Runway

into

2029

Important Data Readouts

2026

#Based on exchange rate of £1.00 to $1.34 and reported cash of £24.3 million as of December 31, 2025

Unlocking the Potential of Immunotherapy

Expression of immune checkpoint molecules

Secretion of cytokines to suppress immune cell function

Reduced antigen presentation by cancer cells

Hypoxic & acidic environment

Recruitment of immunosuppressive cells

Promotion of angiogenic environment

Metabolic reprogramming causes the secretion of immunosuppressive factors

Cordycepin

A Traditional Chinese Medicine found in the Himalayas

3'-dA

Originally isolated from Cordyceps sinensis in1950

3'-dA has potent anti-cancer activity in vitro and can modulate components of the TME

Despite this, it has not been successfully developed due to rapid breakdown by adenosine deaminase

(3'-dA ProTide)

NUC-7738 transforms PD-1 resistant TME into a therapeutically responsive state

Study

Phase 1

Dose Escalation

(monotherapy)

Phase 2

Dose Optimization

(monotherapy)

Phase 2

Dose Confirmation

(combination)

Phase 2

Expansion

(combination)

NUC-7738

completed

pembrolizumab

completed

pembrolizumab

ongoing

Number of patients

Cutaneous Melanoma

Tumor Type

PD-1

inhibitor resistant

PD-1

inhibitor resistant

Exhausted all treatment options

Patient Population

Plasma

Patients (n=27) dosed at 14 - 900 mg/m2

Dose proportional increase in Cmax and AUC

Intracellular

Patients (n=3) dosed at 900 mg/m2

NUC-7738 efficiently generates active anti-cancer metabolite (3'-dATP)

Long half-life of 3'-dATP (42 hrs)

NUC-7738 has been well tolerated

No Grade 4 toxicities ▪ Low rates of Grade 3 toxicities

MTD

Dose AE occurred

(mg/m2)

n=2

n=3

n=2

n=3

112

n=4

182

n=4

273

n=5

400

n=6

600

n=9

750

n=5

900

n=8

1350

n=11

2000

n=2

Total*

n=38

All Grade Treatment-Related Adverse Events (≥10%)

Nausea

1 (33%)

1 (20%)

3 (33%)

2 (40%)

3 (38%)

5 (45%)

1 (50%)

16 (42%)

Fatigue

1 (33%)

1 (17%)

3 (33%)

1 (20%)

3 (38%)

7 (64%)

2 (100%)

14 (37%)

Anemia

2 (25%)

4 (36%)

2 (100%)

7 (18%)

Diarrhea

1 (20%)

1 (13%)

4 (36%)

6 (16%)

Vomiting

1 (20%)

1 (13%)

3 (27%)

1 (50%)

6 (16%)

Mucosal inflammation

1 (11%)

1 (20%)

1 (9%)

1 (50%)

4 (11%)

Decreased appetite

1 (33%)

1 (25%)

1 (20%)

1 (13%)

4 (11%)

Grade 3 Treatment-Related Adverse Events (ALL)

Fatigue

3 (27%)

2 (100%)

4 (11%)

Anemia

1 (13%)

1 (3%)

Neutropenia

1 (11%)

1 (3%)

Vomiting

1 (50%)

1 (3%)

MTD: maximum tolerated dose

n= number of patients receiving each dose level at any time during the study

*total number of patients who experienced TRAE

Disease Control Rate: 41% (Efficacy Evaluable Patients)

NUC-7738 starting dose 14 mg/m2

Stable Disease: 12 months 14% reduction in tumor volume

Treatment duration: 18 months

8 dose escalations

62 years

2 prior lines

nivolumab + ipilimumab: discontinued within 1 month

CK7 inhibitor: progressed at 1 month

Metastatic Melanoma

NUC-7738 starting dose 400 mg/m2

Stable Disease: 9 months

NUC-7738 treatment enabled complete resection

patient had diffuse disease that was inoperable

Treatment duration: 11 months

1 dose escalation

65 years

1 prior line

1) nivolumab + ipilimumab: discontinued within 1 month

Metastatic Melanoma

72 years

1 prior line

1) imatinib: progressed at 19 months

Metastatic Clival Chordoma

NUC-7738 dose 1,350 mg/m2

Stable disease: 6 months

45% reduction in mandibular lesion Complete disappearance of lip lesion Bleeding from nasal lesion resolved

NUC-7738 starting dose 42 mg/m2

46% reduction in lung lesion 1

Change in character in lung lesion 2 small dense core

surrounded by a larger diffuse "ground-glass" periphery

Treatment duration: 6 months

4 dose escalations

65 years

2 prior lines

carboplatin + pemetrexed: progressed at 6 months

docetaxel: progressed at 4 months

Metastatic Lung Adenocarcinoma

Dose Confirmation Cohort (n=12)

Phase 2

NUC-7738

(1125 mg/m2)*

pembrolizumab

(200 mg) Q3W

Q1W

NuTide:701 Study

Cutaneous melanoma

Immunotherapy experienced

ECOG PS 0-1

Exhausted all treatment options

Objective

Key endpoints

Establish RP2D

Safety & tolerability

Anti-tumor activity

Patient population

PD-1 inhibitor resistant patients

Prior Therapy: median (range)

2 (1-3)

PD-1 inhibitor

PD-1 inhibitor (adjuvant)

PD-1 inhibitor (non-adjuvant)

CTLA-4 inhibitor

PD-1 + CTLA-4 inhibitor

BRAF + MEK inhibitor

*Starting dose was 1125 mg/m2 which was escalated to 1350 mg/m2 if well tolerated

NUC-7738 + pembrolizumab has been well tolerated (n=12)

Low rates of Grade ≥3 toxicities ▪ 1 patient experienced Grade 4 transaminitis (ALT/AST increased)

Treatment Related Adverse Events

All Grades n(%)

Grade 3 n(%)

Grade 4 n(%)

Nausea

9 (75)

ALT increased

6 (50)

1 (8)

Diarrhea

6 (50)

1 (8)

Vomiting

6 (50)

1 (8)

Fatigue

5 (42)

1 (8)

Anemia

5 (42)

AST increased

4 (33)

1 (8)

ALP increased

2 (17)

GGT increased

2 (17)

1 (8)

Blood magnesium decreased

2 (17)

Blood sodium decreased

2 (17)

Decreased appetite

2 (17)

Hypophosphatemia

2 (17)

Rash

2 (17)

All Grade TRAEs with prevalence ≥10% patients related to NUC-7738, pembrolizumab or both

Additional Grade 3 TRAEs ≤10%: abdominal pain (1 pt); hypertension (1pt); immune-mediated hepatitis (1 pt); adrenal insufficiency, hypercalcemia and hypotension (1 pt). No additional Grade 4 TRAEs

‡

Patient previously refractory to PD-1 inhibitor (nivolumab) + CTLA-4 inhibitor (ipilimumab) had 55% reduction#

Patient with progression on three prior PD-1 therapies (nivolumab x1, pembrolizumab x2) achieved a 32% tumour reduction‡

Patient who progressed after PD-1 inhibitor (nivolumab) + CTLA-4 inhibitor (ipilimumab) has ongoing complete metabolic response*

# Discontinued by patient choice; follow-up imaging showed progression of non-target lesion, target lesions remained stable (−55%)

Disclaimer

NuCana plc published this content on May 06, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 06, 2026 at 09:17 UTC.